Axsome Therapeutics Acquires Baergic Bio
Axsome Therapeutics reported on November 5 that it acquired Baergic Bio, Inc. from Avenue Therapeutics for $0.3 million. Founded in December 2019, Baergic Bio is a clinical-stage pharmaceutical company that focuses on the development of a pharmaceutical product for the treatment of CNS disorders. Axsome Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders. According to its financial reports, the company reported $385.7 million in revenue for the full year 2024. Avenue Therapeutics, a specialty pharmaceutical company, initially purchased Baergic Bio in 2022. The transaction... Read More »
Advent International Sells Zentiva to GTCR
Advent International, a private equity firm focused on buyouts of companies, announced on September 11 that it sold Zentiva to GTCR. Zentiva is a leading European generics pharmaceutical company with a focus on developing, producing and delivering affordable medicines to more than 100 million people in more than 30 countries across Europe and beyond. Zentiva has four wholly owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Founded in 1980, GTCR is a private equity firm focused on investing in growth companies in the business and consumer services, financial services and technology, healthcare and technology and media and... Read More »
CapVest To Buy Majority Stake In STADA
CapVest Partners has signed an agreement with Bain Capital and Cinven to acquire a majority stake in STADA Arzneimittel AG. STADA Arzneimittel manufactures and distributes specialty pharmaceuticals and non-prescription consumer health products. Located in Bad Vilbel, Germany, STADA has evolved from a traditional generics business into a diversified global healthcare platform since its acquisition by Bain Capital and Cinven in 2017. CapVest Partners is an established European mid-market private equity firm focused on acquiring market leading companies supplying essential products and services. CapVest was formed in 1999 and is based in London. The lead financial advisors to CapVest were... Read More »
Knight Therapeutics Acquires Endo’s Pharmaceutical Businesses for up to $105 Million
Endo, Inc., a generic and specialty branded pharmaceutical company, announced that it was selling its international pharmaceutical businesses to Knight Therapeutics Inc. The businesses are primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma Inc. Total cash consideration for the sale is up to approximately $105 million, consisting of approximately $79 million paid at closing, approximately $11 million related to certain permitted holdbacks and up to $15 million in future payments contingent upon the achievement of certain milestones. Knight Therapeutics Inc. is a specialty pharmaceutical company. In 2024, according to the company’s... Read More »
Norgine Strengthens Rare Disease Portfolio With Theravia Acquisition
Norgine has announced that it acquired Theravia, an international pharmaceutical company specializing in treatments for patients with rare and debilitating conditions, from Mérieux Equity Partners. Theravia has several products in the rare disease space, including SIKLOS®, for adults and children with sickle cell disease, and ORPHACOL®, a medicine for adults and children who have a genetic disorder that affects bile production by the liver. The development of Theravia in the past few years has been supported by its majority shareholder Mérieux Equity Partners, a healthcare dedicated investment firm based in France. Norgine is a specialty pharmaceutical and consumer healthcare company. The... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
